Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/106749
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thunnissen, Erik | - |
dc.contributor.author | Weynand, Birgit | - |
dc.contributor.author | Udovicic-Gagula, Dalma | - |
dc.contributor.author | Brcic, Luka | - |
dc.contributor.author | Szolkowska, Malgorzata | - |
dc.contributor.author | Hofman, Paul | - |
dc.contributor.author | Smojver-Ježek, Silvana | - |
dc.contributor.author | Anttila, Sisko | - |
dc.contributor.author | Calabrese, Fiorella | - |
dc.contributor.author | Kern, Izidor | - |
dc.contributor.author | Skov, Birgit | - |
dc.contributor.author | Perner, Sven | - |
dc.contributor.author | Dale, Vibeke G. | - |
dc.contributor.author | Eri, Zivka | - |
dc.contributor.author | Haragan, Alex | - |
dc.contributor.author | Leonte, Diana | - |
dc.contributor.author | Carvalho, Lina | - |
dc.contributor.author | Prince, Spasenja Savic | - |
dc.contributor.author | Nicholson, Siobhan | - |
dc.contributor.author | Sansano, Irene | - |
dc.contributor.author | Ryska, Ales | - |
dc.date.accessioned | 2023-04-20T11:04:08Z | - |
dc.date.available | 2023-04-20T11:04:08Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2218-6751 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/106749 | - |
dc.description.abstract | A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future. | pt |
dc.language.iso | eng | pt |
dc.publisher | Society for Translational Medicine (STM) | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt |
dc.subject | Lung cancer | pt |
dc.subject | predictive testing | pt |
dc.subject | therapy | pt |
dc.subject | health care | pt |
dc.subject | Europe | pt |
dc.title | Lung cancer biomarker testing: perspective from Europe | pt |
dc.type | article | - |
degois.publication.firstPage | 887 | pt |
degois.publication.lastPage | 897 | pt |
degois.publication.issue | 3 | pt |
degois.publication.title | Translational Lung Cancer Research | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.21037/tlcr.2020.04.07 | pt |
degois.publication.volume | 9 | pt |
dc.date.embargo | 2020-06-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.researchunit | iNOVA4Health - Programme in Translational Medicine (iBET, CEDOC/FCM, IPOLFG and ITQB) | - |
crisitem.author.orcid | 0000-0001-8349-4488 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Lung-cancer-biomarker-testing-Perspective-from-EuropeTranslational-Lung-Cancer-Research.pdf | 1.84 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
23
checked on May 6, 2024
WEB OF SCIENCETM
Citations
22
checked on May 2, 2024
Page view(s)
27
checked on May 7, 2024
Download(s)
23
checked on May 7, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License